RxDoctor Payments Data

Jau Evans

Family · Jacksonville, FLNPI 1497269880

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Viiv Healthcare Company at 36.6% of the total. 2025 is the largest year on record at $1,993, more than ten times the $96 reported in 2022. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,503in general payments, 2019–2025

Across 163 payments — averaging $27.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$1K
  • Theratechnologies Inc.$659
  • Merck$582
  • Napo Pharmaceuticals Inc$96
  • Sanofi$85
  • plus $346 from 13 others

What the payments were for

  • Food & beverage$4,503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,503 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.

See all family providers in Florida →

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala57$216,815
CabenuvaCabotegravir/Rilpivirine13$83,817
DovatoDolutegravir Sodium/Lamivudine22$61,381
TivicayDolutegravir Sodium23$48,997
DescovyEmtricitabine/Tenofov Alafenam23$47,827
XyostedTestosterone Enanthate11$6,015
Albuterol Sulfate HfaAlbuterol Sulfate15$422
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$164
Cyclobenzaprine Hcl13$99
Losartan Potassium16$89
Atorvastatin Calcium17$66
Gabapentin12$50
Levothyroxine Sodium12$48
Amlodipine Besylate23$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,088$264,64280 claims
Viiv Healthcare CompanyCabenuva, Dovato, Tivicay$1,647$194,19558 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.

Other family in Jacksonville

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →